High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Retinal DiseasesTelangiectasis
Interventions
DRUG

ranibizumab 2.0mg

Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections

Trial Locations (1)

80525

Eye Center of Northern Colorado, Fort Collins

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Eye Center of Northern Colorado, P.C.

OTHER